H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences (AURA) with a Buy rating and $22 price target Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating
- Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating
- Aura Biosciences Advances in Cancer Therapy Trials
- Aura Biosciences Raises $69.9 Million in Public Offering
- Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating